Advertisement
Drug Development
Subscribe to Drug Development
View Sample

FREE Email Newsletter

“Flying carpet” technique uses graphene to deliver one-two punch of anticancer drugs

January 6, 2015 10:02 am | by Matt Shipman, News Services, North Carolina State Univ. | News | Comments

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as “flying carpets” to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

Research suggests approach to treat virus causing respiratory illness in children

January 5, 2015 8:01 am | by Emil Venere, Purdue Univ. | News | Comments

New research findings point toward a class of compounds that could be effective in combating infections caused by enterovirus D68, which has stricken children with serious respiratory infections in the U.S. and elsewhere. The researchers used x-ray crystallography to learn the precise structure of the original strain of EV-D68 on its own and when bound to an anti-viral compound called "pleconaril."

Predicting superbugs’ countermoves to new drugs

January 5, 2015 7:29 am | by Robin Ann Smith, Duke Univ. | News | Comments

With drug-resistant bacteria on the rise, even common infections that were easily controlled for decades are proving trickier to treat with standard antibiotics. New drugs are desperately needed, but so are ways to maximize the effective lifespan of these drugs. To accomplish that, Duke Univ. researchers used software they developed to predict a constantly evolving infectious bacterium's countermoves to one of these new drugs ahead of time.

Advertisement

Shelton drug development lab targets Ebola cure

January 3, 2015 5:35 am | by By Ed Stannard - New Haven Register - Associated Press | News | Comments

A company that is developing new anti-viral drugs hopes it will have a cure for Ebola, which is still in the research phase, put on the fast track for development in the fight against the disease. NanoViricides, whose headquarters are in West Haven, opened its research and development lab in July. The company, with a net worth of $250 million, employs more than 20 and expects to double that in the next two years.

Testing anti-drinking drug with help of a fake bar

January 2, 2015 3:39 pm | by By Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

The tequila sure looks real, so do the beer taps. Inside the hospital at the National Institutes of Health, researchers are testing a possible new treatment to help heavy drinkers cut back, using a replica of a fully stocked bar. The idea: Sitting in the dimly lit bar-laboratory should cue the volunteers' brains to crave a drink, and help determine if the experimental pill counters that urge.

FDA drug approvals reached 18-year high in 2014

January 2, 2015 3:39 pm | by By Matthew Perrone - AP Health Writer - Associated Press | News | Comments

The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years. FDA drug approvals are considered a barometer of industry innovation and the federal government's efficiency in reviewing new therapies. Last year's total was the most since the all-time high of 53 drugs approved in 1996.

Landmark discovery in gold nanorod instability

December 18, 2014 3:14 pm | News | Comments

Researchers at Swinburne University of Technology have discovered an instability in gold nanoparticles that is critical for their application in future technology. Gold nanorods are important building blocks for future applications in solar cells, cancer therapy and optical circuitry.

Cancer patients employ mice as avatars

December 15, 2014 3:23 pm | by Associated Press, Marilynn Marchione | News | Comments

Scientists often test drugs in mice. Now some cancer patients are doing the same—with the hope of curing their own disease. They are paying a private lab to breed mice that carry bits of their own tumors so treatments can be tried first on the customized rodents. The idea is to see which drugs might work best on a specific person's cancer.

Advertisement

Improving Patient Access through Public-Private Partnerships

December 15, 2014 1:20 pm | by Brian Goff, Global Franchise Head, Hemophilia, Baxter BioScience | Articles | Comments

As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.

A Tool for Today’s Complex Health Challenges

December 15, 2014 11:06 am | by Waters Corp. | Articles | Comments

Nearly half of all U.S. adults, nearly 117 million individuals, are living with one or more chronic health conditions. This has become the age of chronic disease, and achieving better outcomes depends on developing tools for research and clinical care that efficiently and accurately address the complex diseases we face today.

Cause of malaria drug resistance in SE Asia identified

December 12, 2014 7:00 am | News | Comments

Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing Plasmodium falciparum parasite. This finding provides public health officials around the world with a way to look for pockets of emerging resistance and potentially eliminate them before they spread.

Ebola vaccine trial suspended after side effects

December 11, 2014 12:12 pm | by Associated Press | News | Comments

Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.                             

Resistance and futility

December 8, 2014 8:09 am | by Elizabeth Cooney, Harvard Univ. | News | Comments

Penicillin, the wonder drug discovered in 1928, works in ways that are still mysterious almost a century later. One of the oldest and most widely used antibiotics, it attacks enzymes that build the bacterial cell wall, a mesh that surrounds the bacterial membrane and gives the cells their integrity and shape. Once that wall is breached, bacteria die, allowing us to recover from infection.

Advertisement

A poisonous cure

December 5, 2014 8:53 am | by Michigan State Univ. Media Communications | News | Comments

Take two poisonous mushrooms, and call me in the morning. While no doctor would ever write this prescription, toxic fungi may hold the secrets to tackling deadly diseases. A team of Michigan State Univ. scientists has discovered an enzyme that is the key to the lethal potency of poisonous mushrooms.

Novel approach to treating asthma

December 4, 2014 7:51 am | by American Chemical Society | News | Comments

Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don’t get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating asthma by targeting the trigger—the allergen—before it can spark an attack. They describe their new compound, which they tested on rats, in the Journal of Medicinal Chemistry.

Ability of HIV to cause AIDS is slowing

December 3, 2014 10:02 am | by Oxford Univ. | News | Comments

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS. The Oxford Univ.-led study also indicates that people infected by HIV are likely to progress to AIDS more slowly—in other words the virus becomes less “virulent”—because of widespread access to antiretroviral therapy (ART).

White House claims progress in Ebola fight

December 2, 2014 2:03 pm | by By Jim Kuhnhenn - Associated Press - Associated Press | News | Comments

The White House says the Obama administration is making strides in the fight against Ebola, citing an expanded hospital network and testing capacity at home and gains confronting the deadly disease in West Africa. To sustain that, President Barack Obama was prodding Congress Tuesday to approve his request for $6.2 billion in emergency spending against the outbreak.

Protein predicts response to new immunotherapy drug

December 1, 2014 11:00 am | by Vicky Agnew, Yale Univ. | News | Comments

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. The trial included patients with melanoma or cancers of the lung, kidney, colon, GI tract, or head and neck, whose tumors were evaluated for PD-L1 expression by a novel assay.

Seeking answers from a mysterious parasite

December 1, 2014 9:48 am | by Anne Trafton, MIT News Office | News | Comments

Toxoplasma gondii is a common parasite often spread by cats. Most people who are infected in Europe or North America show no symptoms at all, and only a few suffer from encephalitis or ocular toxoplasmosis, which can cause blindness. However, in South America, toxoplasmosis is associated with much more severe symptoms.

Ebola vaccine seems safe in first-stage testing

November 26, 2014 6:00 pm | by By Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers reported. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health.

A hybrid vehicle that delivers DNA

November 26, 2014 7:46 am | by Cory Nealon, Univ. at Buffalo | News | Comments

A new hybrid vehicle is under development. Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. The technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite much research, have yet to make a significant impact in the treatment of major illnesses.

How turkeys may be lifesavers

November 25, 2014 4:51 pm | by Todd Hollingshead, Brigham Young Univ. | News | Comments

While the turkey you eat on Thursday will bring your stomach happiness and could probably kick-start an afternoon nap, it may also save your life one day. That’s because the biological machinery needed to produce a potentially life-saving antibiotic is found in turkeys. Looks like there is one more reason to be grateful this Thanksgiving.

Angiogenesis drug could provide treatment for TB

November 25, 2014 9:27 am | by Karl Bates, Duke Univ. | News | Comments

The body responds to tuberculosis infection by locking the bacterial offenders into tiny clusters of immune cells called granulomas, which are a hallmark of the disease. This containment strategy succeeds at first, but eventually the bacteria manage to break out of these intercellular jails and spread throughout the body.

Life’s extremists may be an untapped source of antibacterial drugs

November 24, 2014 9:29 am | by David Salisbury, Vanderbilt Univ. | News | Comments

One of the most mysterious forms of life may turn out to be a rich and untapped source of antibacterial drugs. The mysterious life form is Archaea, a family of single-celled organisms that thrive in environments like boiling hydrothermal pools and smoking deep sea vents which are too extreme for most other species to survive.

Researchers create first inhibitor for enzyme linked to certain cancers

November 21, 2014 7:49 am | by Univ. of California, Irvine | News | Comments

Recent studies showing acid ceramidase (AC) to be upregulated in melanoma, lung and prostate cancers have made the enzyme a desired target for novel synthetic inhibitor compounds. In Angewandte Chemie, scientists with the Univ. of California, Irvine School of Medicine and the Italian Institute of Technology describe the very first class of AC inhibitors that may aid in the efficacy of chemotherapies.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading